Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients.
PARP Inhibitors in Ovarian Cancer
Ghisoni, Eleonora;Giannone, Gaia;Aglietta, Massimo;Sapino, Anna;Valabrega, Giorgio
Last
2018-01-01
Abstract
Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PARP inhibitors in ovarian cancer_Valabrega.pdf
Accesso aperto
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
796.82 kB
Formato
Adobe PDF
|
796.82 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
